Your browser doesn't support javascript.
loading
HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in central and eastern Europe.
Oprea, Cristiana; Quirke, Siobhan; Ianache, Irina; Bursa, Dominik; Antoniak, Sergii; Bogdanic, Nikolina; Vassilenko, Anne I; Aimla, Kersti; Matulionyte, Raimonda; Rukhadze, Nino; Harxhi, Arjan; Fleischhans, Lukás; Lakatos, Botond; Sedlacek, Dalibor; Dragovic, Gordana; Verhaz, Antonija; Yancheva, Nina; Acet, Oguzhan; Protopapas, Konstantinos; Kowalska, Justyna Dominika.
Afiliación
  • Oprea C; Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania.
  • Quirke S; Carol Davila University for Medicine and Pharmacy, Bucharest, Romania.
  • Ianache I; Department of Medicine, Galway University Hospital, Galway, Ireland.
  • Bursa D; Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania.
  • Antoniak S; Carol Davila University for Medicine and Pharmacy, Bucharest, Romania.
  • Bogdanic N; Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
  • Vassilenko AI; Viral Hepatitis and AIDS Department, Gromashevsky Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine.
  • Aimla K; University Hospital for Infectious Diseases, University of Zagreb, School of Medicine, Zagreb, Croatia.
  • Matulionyte R; Global Fund Grant Management Department, Republican Scientific and Practical Center for Medical Technologies, Minsk, Belarus.
  • Rukhadze N; Tartu University Hospital, Tartu, Estonia.
  • Harxhi A; Vilnius University, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Fleischhans L; Infectious Diseases, AIDS and Clinical Immunology Center, Tbilisi, Georgia.
  • Lakatos B; University Hospital Center of Tirana, Infectious Disease Service, Tirana, Albania.
  • Sedlacek D; Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Faculty Hospital Bulovka Hospital, Prague, Czech Republic.
  • Dragovic G; National Institute of Hematology and Infectious Diseases, South-Pest Central Hospital, National Center of HIV, Budapest, Hungary.
  • Verhaz A; Charles University, Faculty of Medicine in Plzen, University Hospital Plzen, Plzen, Czech Republic.
  • Yancheva N; Faculty of Medicine, University of Belgrade, Department of Pharmacology, Clinical Pharmacology and Toxicology, Belgrade, Serbia.
  • Acet O; Department for Infectious Diseases, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
  • Protopapas K; Department for AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Disease Sofia, Sofi, Bulgaria.
  • Kowalska JD; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, Izmir, Turkey.
HIV Med ; 25(3): 343-352, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38014768
ABSTRACT

BACKGROUND:

To date there remains much ambiguity in the literature regarding the immunological interplay between SARS-CoV-2 and HIV and the true risk posed to coinfected individuals. There has been little conclusive data regarding the use of CD4 cell count and HIV viral load stratification as predictors of COVID-19 severity in this cohort.

METHODS:

We performed a retrospective, observational cohort study on people living with HIV (PLWH) who contracted COVID-19 in central and eastern Europe. We enrolled 536 patients from 16 countries using an online survey. We evaluated patient demographics, HIV characteristics and COVID-19 presentation and outcomes. Statistical analysis was performed using SPSS 20.1.

RESULTS:

The majority of the study cohort were male (76.4%) and 152 (28.3%) had a significant medical comorbidity. Median CD4 cell count at COVID-19 diagnosis was 605 cells/µL [interquartile range (IQR) 409-824]. The majority of patients on antiretroviral therapy (ART) were virally suppressed (92%). In univariate analysis, CD4 cell count <350 cells/µL was associated with higher rates of hospitalization (p < 0.0001) and respiratory failure (p < 0.0001). Univariate and multivariate analyses found that an undetectable HIV VL was associated with a lower rate of hospitalization (p < 0.0001), respiratory failure (p < 0.0001), ICU admission or death (p < 0.0001), and with a higher chance of full recovery (p < 0.0001).

CONCLUSION:

We can conclude that detectable HIV viral load was an independent risk factor for severe COVID-19 illness and can be used as a prognostic indicator in this cohort.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Respiratoria / Infecciones por VIH / COVID-19 Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: HIV Med Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2024 Tipo del documento: Article País de afiliación: Rumanía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Respiratoria / Infecciones por VIH / COVID-19 Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: HIV Med Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2024 Tipo del documento: Article País de afiliación: Rumanía
...